Unknown PHASE2 INTERVENTIONAL 1-arm NCT02597387

Clinical Trial of Mitoxantrone HCL Liposome Injection in Patients With Relapsed DLBCL and PT/NKCLs

A Single-arm, Open, Multi-center Phase II Clinical Trial of Mitoxantrone HCL Liposome Injection in Subjects With Relapsed Diffuse Large B-cell Lymphoma and and Peripheral T/NK Lymphomas

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions Relapsed DLBCL and PT/NKCLs

Interventions Mitoxantrone HCL Liposome Injection

Updated 7 times since 2017 Last updated: Aug 15, 2018 Started: Aug 31, 2015 Primary completion: Sep 30, 2018 Completion: Oct 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02597387, this PHASE2 trial focuses on Relapsed DLBCL and PT/NKCLs and remains ongoing. Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., it has been updated 7 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2020 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Sep 2018 — Jun 2020 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE2
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Aug 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Data source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China